Fathom Therapeutics, Formerly Atommap, Raises $47 Million in Oversubscribed Series A Financing to Translate Physics and AI-Enabled Small Molecule Design into Next-Generation Medicines

Financing led by Sutter Hill Ventures; company names new Chief Business Officer, adds independent board member, and establishes Scientific Advisory Board NEW YORK, April 27, 2026 /PRNewswire/ -- Fathom Therapeutics, formerly Atommap Corp., a company that uses quantum chemistry and AI to...